Navigation Links
Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer

l mode of action, including its magnetic resonance imaging detectability, provides the opportunity for Xcytrin to be used in a broad range of cancers. In previously conducted randomized trials, Xcytrin combined with whole brain radiation therapy (WBRT) has been shown to prolong time to neurologic progression in patients with brain metastases from NSCLC. Xcytrin's non-overlapping toxicity makes it an appealing agent to use in combination with standard chemotherapy regimens.

The target for Xcytrin is the enzyme thioredoxin reductase, which is frequently overexpressed in lung cancer cells. This enzyme has been shown to confer to cancer cells characteristics of aggressive tumor growth and resistance to chemotherapy. First-line therapy for advanced NSCLC includes combination chemotherapy using drugs such as carboplatin, cisplatin, Gemzar(R), taxanes and others. Currently approved agents for second-line treatment of NSCLC include Alimta, Tarceva(R) and Taxotere.

About Pharmacyclics

Pharmacyclics is a pharmaceutical company developing innovative products to treat cancer and other serious diseases. The company is leveraging its small-molecule drug development expertise to build a pipeline in oncology and other diseases based on a wide range of targets, pathways and mechanisms. Its lead product, Xcytrin, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating Xcytrin, either as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. A New Drug Application for use of Xcytrin in combination with WBRT for treatment of brain metastases from NSCLC was filed with the Food and Drug Administration in April 2007. More information about the company, its technology, and products can be found at http://www.pharmacyclics.com. In addition, more information about advocacy on behalf of Xcytrin can be found at




Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer
2. Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting
3. Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Brutons Tyrosine Kinase Inhibitors
4. Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Brutons Tyrosine Kinase Inhibitor Compounds
5. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
6. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
8. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
9. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
10. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
Post Your Comments:
(Date:1/23/2015)... JUNCTION, N.J. , Jan. 23, 2015  CytoSorbents ... company commercializing its CytoSorb® extracorporeal cytokine adsorber to ... patients, announced the receipt of $385,642, net of ... participant of the Technology Business Tax Certificate Transfer ...
(Date:1/23/2015)... , Jan. 23, 2015 Tianyin Pharmaceutical Inc. ... that specializes in the development and sale of patented ... and active pharmaceutical ingredients (API) today announced the business ... API operation. 1. Following the September 2014 ...
(Date:1/22/2015)... SAN DIEGO, Jan. 22, 2015  ResMed Inc. (NYSE: ... 31, 2014. Revenue for the quarter was $423.0 million, a ... 2013 (a 14 percent increase on a constant currency basis). ... compared to the quarter ended December 31, 2013. Diluted earnings ...
Breaking Medicine Technology:CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 2CytoSorbents Receives $385,000 in Non-Dilutive Funding from the New Jersey Technology Business Tax Certificate Transfer Program 3TPI's JCM Updates on Import Registration for International Clients 2TPI's JCM Updates on Import Registration for International Clients 3TPI's JCM Updates on Import Registration for International Clients 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11
... Nov. 8, 2011 FDA approved Makena (hydroxyprogesterone caproate) ... of certain preterm births in women who have had ... before Makena was approved, a version of the active ... physicians requested the drug from a pharmacist who compounded ...
... MedBox (Pink Sheets: MDBX ) ( www.thedispensingsolution.com ... symbol to MDBX.  The company previously announced that their ... The company is a leader in the design, ... medicines. The free-standing unit features 60 or more slots ...
Cached Medicine Technology:FDA Statement on Makena 2MedBox Announces Ticker Symbol Change 2
(Date:1/22/2015)... has released a new blog post presenting the basic features ... Purchasing an accidental death and dismemberment rider for a car ... provides benefits if the insured dies in an accident. Accidental ... life insurance. , AD&D is not expensive and can ...
(Date:1/22/2015)... New York, NY (PRWEB) January 22, 2015 ... American College of Sports Medicine flagship journal Medicine ... supplementation with L-Citrulline before exercise may help reduce ... strenuous exercise. 1 , Participants in the ...
(Date:1/22/2015)... January 23, 2015 Recently, Weddingshe.com has added ... and has announced its highest annual revenues in the past ... its popular glamorous wedding dresses. , According to the sales ... wedding dress promotions for them in 2015. This point can ...
(Date:1/22/2015)... years since the release of their debut recording Love is King, ... & Matthew Love – the duo are pleased to announce their ... Swan Records on February 24, 2015. , THE ROAD offers the ... all of us to walk out of the mire of our ...
(Date:1/22/2015)... EBSCO Information Services (EBSCO) and the American ... effort to further promote visibility and adoption of the top ... AMA journals available via its subscription services, EBSCO will now ... , Long known as both a subscription agency and ...
Breaking Medicine News(10 mins):Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 2Health News:THE ROAD by Avasa & Matthew Love -- A New Album 3Health News:THE ROAD by Avasa & Matthew Love -- A New Album 4Health News:EBSCO Expands Partnership with the American Medical Association 2Health News:EBSCO Expands Partnership with the American Medical Association 3Health News:EBSCO Expands Partnership with the American Medical Association 4
... Initiatives taken by European governments and healthcare ... aimed at improving efficiency levels and reducing ... automation is proving to be a major ... pressure from governments across Europe to install ...
... Inc. (Nasdaq: NXXI ), a developer and marketer ... improve cardiovascular health, enhance memory and address chronic joint pain, ... the market - on Tuesday, May 12, 2009 for the ... The Company has scheduled a conference call to review the ...
... Million -- Same-Store Sales Increased 1.1% -- Net Cash Provided ... Improved 18.0% to $17.2 Million - , NEW YORK, May ... for the first quarter ended March 28, 2009. Key Highlights ... Adjusted FIFO EBITDA increased 7.8% to $19.7 million ...
... Hills High School ... Nationwide BETHESDA, Md., May 5 The Cystic Fibrosis Foundation ... will visit Vestavia Hills High School in Birmingham, Ala., to honor ... a life-threatening genetic disease. Students raised more than $17,000 for the ...
... opportunity.” Benjamin Franklin’s significant words uttered more than 250 years ago ... , ... New York, NY (Vocus) May 5, 2009 ... more than 250 years ago ring true for the Gift ...
... CORONA DEL MAR, Calif., May 5 ,Mayday, ... French phrase m,aider ("help me"), was appropriately celebrated ... (ASA) closed public website access to their Newsletter,s ... expert, Dr. Barry Friedberg, be able to document ...
Cached Medicine News:Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 2Health News:Frost & Sullivan: Rising Public Awareness Promoting Acceptance of Infection Surveillance Systems Across Europe 3Health News:Nutrition 21 to Report Third Quarter Fiscal Year 2009 Financial Results on Tuesday, May 12, 2009 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 2Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 3Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 4Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 5Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 6Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 7Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 8Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 9Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 10Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 11Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 12Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 13Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 14Health News:Duane Reade Holdings, Inc. Reports First Quarter 2009 Results 15Health News:CW's 7th Heaven Actress Mackenzie Rosman to Visit Birmingham Area High School to Honor Cystic Fibrosis Foundation Fundraising 2Health News:Bone Marrow Registry to Launch Groundbreaking Fundraising Technology to Overcome Madoff Crisis 2Health News:ASA 'May Day' - Stung By Exposure of Watergate-like Public Record Deletions, American Society of Anesthesiologists Closes Access to Website Newsletter 2
... Designed to accommodate a variety of applications ... the AMAX DestinyPlus is suitable for any ... environment. With a mixed-mode throughput exceeding 95 ... perform a full range of chromogenics, the ...
The TCM4 is able to detect patient changes and is portable....
The TCM400 is the first and only portable instrument to provide up to six simultaneous measurements of transcutaneous oxygen tension (tcpO2)...
... is the only online source of nationally ... critical care nurses and other healthcare professionals., ... so you can take them at your ... certificate is issued upon course completion. The ...
Medicine Products: